One challenge faced by dental professionals is that, unlike natural tooth structure, composite restorations do not lighten when exposed to bleaching agents. As a result, functional restorations may need replacement after bleaching to match the newly whitened teeth. However, replacing a composite restoration can lead to unnecessary removal of tooth structure, potentially weakening the tooth and increasing its susceptibility to further iatrogenic damage. This study will investigate the ability of Omnichroma restorations to shade-match tooth structure after bleaching.
The null hypotheses will be:
1. Single-shade RBC will not exhibit similar shade and optical behavior to conventional RBC across all anterior restorations following bleaching.
2. Patient satisfaction regarding color blending between the restoration and tooth structure will not differ according to the type of material used.
3. Dentist satisfaction regarding color blending between the restoration and tooth structure will not differ according to the type of material used.

Start Date10 Mar 2025

Sponsor / Collaborator

King Abdullah University Hospital

RBR-2y7jf2c

/ Not yet recruitingNot ApplicableIIT

Efiicacy of brush-on vs. tray-delivery at-home bleaching with 6% hydrogen peroxide: A randomized, single-blind, split-mouth controlled trial

Start Date10 Feb 2025

Sponsor / Collaborator

Universidade Estadual de Ponta Grossa

[+1]

RBR-98zsxkw

/ Not yet recruitingNot ApplicableIIT

Efficacy of In-office Bleaching using 35% Hydrogen Peroxide in an attachable syringe varying the application tip: double-blind randomized clinical trial

Start Date15 Oct 2024

Sponsor / Collaborator

Universidade Estadual de Ponta Grossa

[+1]

100 Clinical Results associated with Hydrogen Peroxide

100 Translational Medicine associated with Hydrogen Peroxide

100 Patents (Medical) associated with Hydrogen Peroxide

254,575

Literatures (Medical) associated with Hydrogen Peroxide

31 Dec 2025·Virulence

Decarboxylase mediated oxalic acid metabolism is important to antioxidation and detoxification rather than pathogenicity in Magnaporthe oryzae

Article

Author: He, Zhengquan ; Wei, Yi ; Fan, Xiaoning ; Zhang, Shihong ; Liu, Chang ; Dang, Yuejia ; Hu, Yan ; Batool, Wajjiha

Oxalic acid (OA), an essential pathogenic factor, has been identified in several plant pathogens, and researchers are currently pursuing studies on interference with OA metabolism as a treatment for related diseases. However, the metabolic route in Magnaporthe oryzae remains unknown. In this study, we describe D-erythroascorbic acid-mediated OA synthesis and its metabolic and clearance pathways in rice blast fungus. By knocking out the D-arabino-1,4-lactone oxidase gene (Moalo1), one-third of oxalic acid remained in M. oryzae, indicating a main pathway for oxalic acid production. M. oryzae OxdC (MoOxdC) is an oxalate decarboxylase that appears to play a role in relieving oxalic acid toxicity. Loss of Mooxdc does not affect mycelial growth, conidiophore development, or appressorium formation in M. oryzae; however, the antioxidant and pathogenic abilities of the mutant were enhanced. This is owing to Mooxdc deletion upregulated a series of OA metabolic genes, including the oxalate oxidase gene (Mooxo) and Moalo1, as well as both OA transporter genes. Simultaneously, as feedback to the tricarboxylic acid (TCA) cycle, the decrease of formic acid in ΔMooxdc leads to the reduction of acetyl-CoA content, and two genes involved in the β-oxidation of fatty acids were also upregulated, which enhanced the fatty acid metabolism of the ΔMooxdc. Overall, this work reveals the role of OA in M. oryzae. We found that OA metabolism was mainly involved in the growth and development of M. oryzae, OA as a byproduct of D-erythroascorbic acid after removing H₂O₂, the OA-associated pathway ensures the TCA process and ATP supply.

31 Dec 2025·Plant Signaling & Behavior

Expression characteristics of CsESA1 in citrus and analysis of its interacting protein

Article

Author: Wei, Wei ; Wang, Huiying ; Zuo, Jiaqi ; He, Xiao ; Han, Ziyue ; He, Qing

The most damaging disease affecting citrus globally is Huanglongbing (HLB), primarily attributed to the infection by 'Candidatus Liberibacter asiaticus' (CaLas). Based on comparative transcriptome data, two cellulose synthase (CESA) genes responsive to CaLas infection induction were screened, and one gene cloned with higher differential expression level was selected and named CsCESA1. we verified the interaction between CsCESA1 and citrus exopolysaccharide 2 (CsEPS2) proteins. Subcellular localization in tobacco indicated that both CsCESA1 and CsEPS2 proteins are primarily located in the nucleus and cytoplasm. RT-qPCR analysis indicated that the expression levels of CsCESA1 and CsEPS2 were associated with variety tolerance, tissue site, and symptom development. Furthermore, we generated CsCESA1 and CsEPS2 silencing plants and obtained CsCESA1 and CsEPS2 silencing and overexpressing hairy roots. The analysis of hormone content and gene expression also showed that CsCESA1 and CsEPS2 are involved in transcriptional regulation of genes involved in systemic acquired resistance (SAR) response. In conclusion, our results suggested that CsCESA1 and CsEPS2 could serve as potential resistance genes for HLB disease, offering insights into the plant's defense mechanisms against HLB.

31 Dec 2025·Italian Journal of Animal Science

Effects of dietary chlorogenic acid supplementation on laying performance, egg quality, antioxidant capacity, and liver lipid metabolism in late-peak laying hens

Author: Sun, Yue ; Zhao, Haitong ; Guo, Lianxiang ; Yan, Ming ; Zhu, Mingkun ; Hong, Yan

This investigation focused on the effects of chlorogenic acid (CGA) on laying performance, egg quality, antioxidant capacity, and liver lipid metabolism in late-peak laying hens.Two hundred forty 43-wk-old Hy-Line Brown laying hens were randomly distributed into 4 treatments receiving 0, 400, 600, and 800 mg/kg CGA for twelve weeks.Egg production rate and average egg weight were significantly elevated with 600 and 800 mg/kg CGA relative to the control group.Significant improvements were also noted in the Haugh unit, albumen height, and yolk color in both CGA groups, along with elevated levels of ovomucin in the albumen and lutein in the yolk.CGA at 600 and 800 mg/kg doses significantly reduced serum hydrogen peroxide and malondialdehyde levels, as well as hepatic malondialdehyde levels.Meanwhile, CGA treatment significantly upregulated hepatic Nrf2 and SOD2 gene expression while downregulating Keap1 gene expression.Addnl., 600 and 800 mg/kg CGA treatment significantly decreased serum TG, T-CHO, and LDL-C levels, as well as liver TG and T-CHO levels, while increasing serum lipoprotein lipase activity.Moreover, CGA treatment significantly decreased hepatocyte lipid droplet levels, along with a notable reduction in SREBP1, FASN, ACC, and DGAT2 gene expressions, and a significant upregulation in PPARα, ACOX1, and CPT1 gene expressions.Our findings demonstrate that CGA can improve laying performance, egg quality, and antioxidant capacity, and reduce liver lipid accumulation by inhibiting fatty acid synthesis and stimulating fatty acid oxidation in late-peak laying hens.A dietary supplement of 600-800 mg/kg CGA is recommended under the current exptl. conditions.HIGHLIGHTSDietary supplementation CGA improved the laying performance, egg quality, and antioxidant capacity in the late-peak laying hens.CGA reduced hepatic lipid accumulation by inhibiting fatty acid synthesis and stimulating fatty acid oxidationUnder the current exptl. conditions, a dietary supplemental level of 600-800 mg/kg CGA is recommended for laying hens.

107

News (Medical) associated with Hydrogen Peroxide

09 Apr 2025

·www.prnewswire.com

If Your Pet Eats Something Toxic, Hold the Hydrogen Peroxide

Treating a Poisoned Pet at Home Can Still Require Medical Assistance MINNEAPOLIS, April 9, 2025 /PRNewswire/ -- Every pet owner knows that something dropped on the floor, or left on a counter, can be fair game for the family pet to eat, but that's not the only way animals get into a potentially toxic situation. Pets are also accidentally given the wrong medication, or they get into food that is perfectly healthy for humans, but toxic to pets. Continue Reading Toxicology experts recommend consulting a veterinary medical professional before giving dogs like Daisy hydrogen peroxide to induce vomiting. When an item ingested is toxic to your furry or feathered family member, the first thought might be to induce vomiting immediately, but the toxicology experts at Pet Poison Helpline recommend calling a medical professional first. "Many pets are motivated by food, especially dogs, so when something is dropped or left on the floor, they assume it is edible" said Dr. Renee Schmid, a senior veterinary toxicologist and director of Veterinary Medicine at Pet Poison Helpline. "We've had many pet owners who call us because they've dropped or given their pet the wrong medication. Dogs are also curious by nature, and explore new things with their mouths, often leading to unfortunate ingestions. If your pet does have an accidental poisoning, you may cause more harm by inducing vomiting on your own." In a recent case, one pet owner accidentally gave her dog her human cancer medication. As soon as she realized what had happened, she forced the dog to drink a dangerous amount of hydrogen peroxide. The cancer pill was retrieved, but the hydrogen peroxide caused the dog to continue vomiting and stop eating. It did significant damage to the dog's gastrointestinal (GI) system. Fortunately, the dog was treated with medication to help as the stomach recovered and has returned to full health. "Hydrogen peroxide, when used properly, can be very effective at inducing vomiting in dogs only," explained Dr. Schmid. "If given in too great a quantity, however, it can cause significant damage to the esophagus, stomach and intestinal tract." In certain situations, dogs are the only animal that may be able to have vomiting attempted at home with hydrogen peroxide. Cats, birds, and other species should never have vomiting attempted at home due to high risks of potentially fatal consequences. Negative effects may also occur if vomiting is attempted at home in dogs, which makes it important to never attempt without consulting a veterinarian or Pet Poison Helpline. In another case, a Sheltie in Pennsylvania gobbled up some raisins before his owner could stop him. Grapes, raisins and currants are toxic to dogs. Ingestion of even a small amount of these foods can result in severe, acute kidney failure. "Fortunately, the owner called Pet Poison Helpline before trying to induce vomiting at home," Dr. Schmid said. "We were able to walk him through the process of administering the correct amount of hydrogen peroxide, and he was able to safely retrieve the raisins before they caused any harm." This treatment was potentially lifesaving for the pet and avoided the need for aggressive medical care. It is always ideal for vomiting, or emesis as it is known medically, to be performed under the care of a veterinarian. This is because they can administer medications that generally have fewer potential negative effects and can intervene if the pet has any issues during the process. In emergency poisoning situations, however, timing is often of the essence and home emesis may need to be considered in dogs if veterinary care is not readily available. "To be safe, pet owners should try to consult with a veterinary professional first in case of accidentally poisoning," Dr. Schmid added. "If your regular veterinarian isn't available, the toxicology experts at Pet Poison Helpline are here to help." About Pet Poison Helpline Pet Poison Helpline®, your trusted source for toxicology and pet health advice in times of potential emergency, is available 24 hours, seven days a week for pet owners and veterinary professionals who require assistance treating a potentially poisoned pet. Per incident and subscription service options are available. We are an independent, nationally recognized animal poison control center triple licensed by the Boards of Veterinary Medicine, Medicine and Pharmacy providing unmatched professional leadership and expertise. Our veterinarians and board-certified toxicologists provide treatment advice for all species, including dogs, cats, birds, small mammals, large animals and exotic species. As the most cost-effective option for animal poison control care, Pet Poison Helpline's fee of $89 per incident includes follow-up consultations for the duration of the case. The company also offers pethelpline(SM) and pethelplinePRO(SM) subscription services directly to pet lovers. Based in Minneapolis, Pet Poison Helpline is available in North America by calling 800-213-6680. Additional information can be found online at . Contact: Curtis Steinhoff Pet Poison Helpline® (602) 300-8466 [email protected] SOURCE Pet Poison Helpline WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

25 Mar 2025

·www.globenewswire.com

TOMI Environmental Solutions, Inc. Partners with Pharma Biotech System Components to Enhance Disinfection Solutions

FREDERICK, Md., March 25, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a leader in disinfection and decontamination solutions, today announced an OEM partnership with Pharma Biotech System Components LLC/Pharma Biotech System Components Ltd (PBSC), a premier manufacturer specializing in high containment, material decontamination, and cleanroom solutions. This collaboration enhances TOMI's SteraMist Integrated System (SIS) product launched in the second half of last year. Through this OEM agreement, TOMI will now offer pass-through hatches and chambers integrated with iHP, specifically designed for optimized decontamination cycles. PBSC is one of the leading manufacturers of Cleanroom, High Containment, and Material Decontamination products worldwide, offering an extensive product range, bespoke designs, and assembly capabilities. Catering to the needs of customers with high-quality products and services within the Pharmaceutical, Medical Research, high Containment, and Hospital sectors around the world. This partnership enables TOMI to leverage PBSC’s expertise in high-containment enclosures while expanding the adoption of SteraMist in critical industries. Through integration with PBSC’s designs, TOMI’s SIS provides an efficient method for achieving high-level disinfection in critical environments. Several projects are currently underway, showcasing the strong market demand for this innovative system. "We are excited to formalize our partnership with PBSC," said Elissa J. (E.J.) Shane, COO of TOMI Environmental Solutions. "This agreement represents a significant advancement in fulfilling the increasing demand for iHP-integrated disinfection solutions. We are experiencing strong interest and are actively marketing and bidding on projects utilizing SIS products and high-quality pass-through hatches and chambers offered by PBSC." TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments. For additional information, please visit http://www.steramist.com or contact us at info@tomimist.com Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products to serve life science sectors. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT:John Nesbett/Rosalyn ChristianIMS Investor Relationstomi@imsinvestorrelations.com

License out/in

24 Mar 2025

·www.medicaldesignandoutsourcing.com

Steris reaches deal to settle ethylene oxide cases in Illinois

Steris said this month that its Isomedix subsidiary reached a deal with confidential settlements to resolve personal injury claims from people who said they were harmed by a ethylene oxide (EtO) sterilization facility in Illinois. Isomedix will pay up to $48.15 million to settle the claims, according to a securities filing, which said “the settlement agreements are expected to resolve substantially all of the claims for personal injury related to ethylene oxide (“EO”) that are currently pending in the Circuit Court of Cook County, Illinois.” Steris said it plans to record a charge for the settlement for fiscal 2025 (which ends March 31), and that the charge won’t be included in the company’s adjusted earnings measures for fiscal 2025. The company said the deals are not “an admission of liability or that emissions from the Waukegan, Illinois facility ever posed a safety hazard to the people who live or work in the surrounding areas.” Previously: EPA flags high-cancer-risk EtO sterilization facilities across the country The first case went before a jury last year in a trial that started in December and ended in January with a mistrial. (The Cook County Record has more details about that first case.) Isomedix could walk away from the deal “if certain agreed terms are not fulfilled, including if a substantial majority of plaintiffs in such cases do not agree to settle or are disqualified under the applicable terms or the resulting settlements are ultimately not approved by the court.” “In the event it exercises its walkaway rights, Isomedix is prepared to continue to defend itself in the litigation and reserves all legal and factual defenses against such claims,” Steris continued in the filing. “… Isomedix anticipates dismissal of all pending EO-related claims brought by the covered plaintiffs upon completion of the claims administration process and approval by the court.” Steris did not say how many lawsuits the settlements cover. In November, the medical device company — which provides contract sterilization for medical device manufacturers through its Applied Sterilization Technologies (AST) unit and makes sterile products for hospitals — disclosed hundreds of EtO lawsuits. Steris operated the sterilization plant from January 2005 to September 2008 under the Isomedix brand. Steris purchased Isomedix in 1997; it is now a part of AST. Steris is the world’s 15th-largest medical device company, according to Medical Design & Outsourcing‘s 2024 Medtech Big 100 ranking by revenue. EtO is used on about 20 billion medical devices each year (approximately half of all sterile medical devices) and alternative methods are not yet sufficient for existing demand. Rather than banning EtO due to its health risks, the Environmental Protection Agency has increased regulation of the chemical while the medtech industry and FDA work on improving sterilization safety. Last year, the FDA’s sterilization innovation partnership with device manufacturers and commercial sterilizers led to the addition of vaporized hydrogen peroxide (VHP) as an Established Category A sterilization method for medical devices. Read more: Taking medical device sterilization in-house with vaporized hydrogen peroxide (VHP)

Acquisition

100 Deals associated with Hydrogen Peroxide

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Keratosis, Seborrheic	United States	Aclaris Therapeutics, Inc.	14 Dec 2017
Disinfectants	Japan	Ebisu Yakuhin Kako KK	01 Mar 1986
Wound Infection	China	Tianjin Dongfang Guangcheng Pharmaceutical Chemical Co., Ltd.	01 Jan 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acne Vulgaris	Phase 3	United States	Aclaris Therapeutics, Inc.	17 Sep 2018
Warts	Phase 3	United States	Aclaris Therapeutics, Inc.	13 Sep 2018
Dermatosis Papulosa Nigra	Phase 2	United States	Aclaris Therapeutics, Inc.	26 Jun 2017
Visible Lesion	Phase 2	United States	Aclaris Therapeutics, Inc.	26 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASTRO2024	Not Applicable	Rectal Cancer	-	Hydrogen Peroxide + Neoadjuvant Chemoradiotherapy	kvwdauialv(fbttferbyn) = significantly more patients with grade 2 proctitis were observed in the IG (IG; 30%, HC; 0%; p<0.01) and 2 patients showed grade 2 hemorrhage in the IG but none in the HC bnxlqmmqwu (ckmjmldosv ) View more	-	01 Oct 2024
				Neoadjuvant Chemoradiotherapy
DDW2024	Not Applicable	Pancreatic Diseases	-	hydrogen peroxide (Direct endoscopic necrosectomy (DEN))	uymnkrpsca(oqncjfzocf) = pzayedrkuz tggfqakyss (xssgvxyckn, 4.5 - 11.6) View more	-	19 May 2024
				Direct endoscopic necrosectomy with hydrogen peroxide	uymnkrpsca(oqncjfzocf) = iproutlrur tggfqakyss (xssgvxyckn, 2.5 - 17.0) View more
NCT03262701 (AHP, CTgov)	Phase 4	Chronic Periodontitis	42	Hydrogen Peroxide (Hydrogen Peroxide Gel for 13weeks)	qzldbealbh(dacwshnohf) = cgwnktbxcb lephdpqdbq (bcdsjabust, 0.16) View more	-	21 Dec 2022
				Hydrogen Peroxide (Hydrogen Peroxide Gel for 26weeks)	qzldbealbh(dacwshnohf) = hauxiusaad lephdpqdbq (bcdsjabust, 0.05) View more
NCT03687372 (CTgov)	Phase 3	Warts	503	vehicle	sevnjlpqsh(jmmxkhdcvz) = nqwyrisagp kmzlyeveus (aurwrzczup, dfrrgvdggl - xwdiyoojax) View more	-	05 Oct 2020
NCT03691831 (CTgov)	Phase 3	Warts	502	Active (Active)	ixuvdbgmrw = yinlxjukie voqgwjtdsg (itmoafxlgw, blagbaxmcx - gevrgluxye) View more	-	05 Oct 2020
				Vehicle (Vehicle)	ixuvdbgmrw = mexoiqwvtb voqgwjtdsg (itmoafxlgw, lfstfxtjti - qpcdenoign) View more
NCT03224598 (CTgov)	Phase 2	Dermatosis Papulosa Nigra	39	A-101 Topical Solution 40% (No Medical Abrading)	uumzymvjwx(hdxlsclkna) = efkuypacvf awyhhtroqo (xqjppkrjjz, 0.52) View more	-	17 Mar 2020
				A-101 Topical Solution 40% (Medically Abrading)	uumzymvjwx(hdxlsclkna) = qjltoghndl awyhhtroqo (xqjppkrjjz, 0.90) View more
NCT03487588 (SK-FAN, CTgov)	Phase 4	Keratosis, Seborrheic	41	A-101 Topical Solution	hsudrcbhbn(szxlcpotid) = tkpnqhgydd nudkemdtff (rietakbdsr, 0.62) View more	-	02 Oct 2019
ERS2019	Not Applicable	-	-	Hydrogen peroxide (H2O2)	tmvxjlhfkx(obzwubuufq) = hhyfpdirev onjpoaxuic (lyctlpvjfv )	-	28 Sep 2019
NCT03148691 (CTgov)	Phase 2	Keratosis, Seborrheic	253	A-101 (Vehicle)	wjidbrevcd(watodfgwmj) = xvyesonrzb avpnsaalqh (vulqadtatz, 10.4) View more	-	06 May 2019
				A-101 (A-101 Low Dose)	wjidbrevcd(watodfgwmj) = mjjzhhlyzv avpnsaalqh (vulqadtatz, 36.74) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hydrogen Peroxide

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation